載入中
HKSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
HK$2.085
−HK$0.025 · -1.18%
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
最新資料
HK$2.085
−HK$0.025 · -1.18%
盤中時間採用HKT。市場資料可能有所延遲。
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
日內區間
目前HK$2.085
52週區間
目前HK$2.085
盤中時間採用HKT。市場資料可能有所延遲。
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
日內區間
目前HK$2.085
52週區間
目前HK$2.085
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.8億 CNY | 2.56億 CNY | 7661萬 CNY | 1759.9萬 CNY | — |
| 銷貨成本 | 2.07億 CNY | 1.31億 CNY | 3923.6萬 CNY | 991萬 CNY | 3847.64萬 CNY |
| 毛利 | 2.73億 CNY | 1.25億 CNY | 3737.4萬 CNY | 768.9萬 CNY | −3847.64萬 CNY |
| 研究與開發 | 1.42億 CNY | 2.15億 CNY | 1.72億 CNY | 1.3億 CNY | 1.87億 CNY |
| 銷售、一般及管理費用 | 2.8億 CNY | 2.7億 CNY | 2.04億 CNY | 1.45億 CNY | 1.35億 CNY |
| 營業費用 | 4.14億 CNY | 4.77億 CNY | 3.75億 CNY | 2.75億 CNY | 3.22億 CNY |
| 利息收入 | 1118.97萬 CNY | 1343.8萬 CNY | 1651.2萬 CNY | 424萬 CNY | 503.6萬 CNY |
| 利息支出 | 793.52萬 CNY | 860.9萬 CNY | 790.7萬 CNY | 366.7萬 CNY | 395萬 CNY |
| 折舊和攤銷 | 3246.8萬 CNY | 3458.3萬 CNY | 3623.8萬 CNY | 3177.7萬 CNY | 3158.9萬 CNY |
| 營業利益 | −1.41億 CNY | −3.53億 CNY | −2.89億 CNY | −2.67億 CNY | −3.21億 CNY |
| 淨利 | 10.78億 CNY | −2.5億 CNY | −2.11億 CNY | −2.04億 CNY | −3.31億 CNY |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM55.1萬0.00%175.99億 USD0.07%US$52.15+0.06%
Avantis Emerging Markets Equity ETFAVEM22.74萬—281.39億 USD0.33%US$92.82-0.48%
Avantis Emerging Markets Value ETFAVES13.99萬0.01%15.61億 USD0.36%US$65.29-0.03%
Dimensional World ex U.S. Core Equity 2 ETFDFAX4.94萬0.00%123.22億 USD0.28%US$37.00+0.22%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM3.95萬0.00%96.11億 USD0.39%US$39.46-0.53%
Dimensional - Emerging Core Equity Market ETFDFAE3.94萬0.00%100.47億 USD0.29%US$38.88-0.46%
State Street SPDR S&P China ETFGXC2.79萬0.01%4.52億 USD0.59%US$85.78+0.11%
Avantis Emerging Markets Small Cap Equity ETFAVEE1658.83—1.39億 USD0.42%US$69.23-0.40%State Street SPDR Portfolio Emerging Markets ETFSPEMAvantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR S&P China ETFGXCAvantis Emerging Markets Small Cap Equity ETFAVEEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
